RO 282653Alternative Names: ROCHE 282653
Latest Information Update: 19 Sep 2006
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for Prostate cancer in Germany (unspecified route)
- 07 May 2003 Preclinical trials in Prostate cancer in Germany (unspecified route)